Reducing Cardiometabolic Risk: What Cardiovascular Outcomes Trials Tell Us About Incretin-Based Therapies
Please visit answersincme.com/KAF860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Jill Trinacty, MD, FRCPC, ABOM. In this activity, an expert in endocrinology discusses incretin-based therapies for the management of cardiometabolic risk. Upon completion of this activity, participants should be better able to: Describe the role of incretin-based therapies in cardiovascular risk reduction; Compare cardiovascular outcomes evidence across incretin-based therapies to inform clinical discussions; and Recognize opportunities to identify and address cardiometabolic risk in a multidisciplinary team setting.
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Listen to This Episode
More from CME in Minutes: Education in Primary Care
Managing Type 2 Diabetes Today: Supporting Individualized, Team-Based Care
Expanding the Use of HER2-Directed ADCs Into Early-Stage Breast Cancer: Multidisciplinary Conversations on (Neo)Adjuvant Care
KIT D816V in Focus: Optimizing Diagnosis and TKI Therapy in Advanced Systemic Mastocytosis
Managing Obesity and Obstructive Sleep Apnea Together: Practical Approaches to Diagnosis, Treatment, and Ongoing Reassessment
Get summaries like this every morning.
Free AI-powered recaps of CME in Minutes: Education in Primary Care and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.